Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
17
ASRT Quote, Financials, Valuation and Earnings
Last price:
$0.66
Seasonality move
:
26.06%
Day range:
$0.61 - $0.67
52-week range:
$0.51 - $1.01
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.47x
P/B ratio:
0.60x
Volume:
1.4M
Avg. volume:
466K
1-year change:
-24.68%
Market cap:
$63.5M
Revenue:
$125M
EPS (TTM):
-$0.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ASRT
Assertio Holdings, Inc.
|
$27M | -- | -7.48% | -100% | $2.66 |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
FGEN
FibroGen, Inc.
|
$1.6M | -$4.01 | -46.75% | -5.74% | $43.00 |
|
MYO
Myomo, Inc.
|
$9.4M | -$0.11 | -13.8% | -1168.66% | $5.00 |
|
SKYE
Skye Bioscience, Inc.
|
-- | -$0.32 | -- | -25.79% | $8.25 |
|
TBPH
Theravance Biopharma, Inc.
|
$19.9M | -$0.05 | 129.3% | -80.69% | $26.71 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ASRT
Assertio Holdings, Inc.
|
$0.66 | $2.66 | $63.5M | -- | $0.00 | 0% | 0.47x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8150 | $12.3077 | $209.3M | -- | $0.00 | 0% | 190.87x |
|
FGEN
FibroGen, Inc.
|
$8.59 | $43.00 | $34.7M | 0.22x | $0.00 | 0% | 29.24x |
|
MYO
Myomo, Inc.
|
$1.02 | $5.00 | $39.2M | -- | $0.00 | 0% | 1.00x |
|
SKYE
Skye Bioscience, Inc.
|
$0.83 | $8.25 | $26.7M | -- | $0.00 | 0% | 476.49x |
|
TBPH
Theravance Biopharma, Inc.
|
$18.73 | $26.71 | $949.1M | 33.30x | $0.00 | 0% | 11.75x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ASRT
Assertio Holdings, Inc.
|
29.83% | 1.300 | 53.04% | 1.43x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
FGEN
FibroGen, Inc.
|
524.43% | 0.121 | 25.04% | 3.28x |
|
MYO
Myomo, Inc.
|
45.68% | -2.855 | 35.87% | 1.94x |
|
SKYE
Skye Bioscience, Inc.
|
0.97% | 6.173 | 0.26% | 4.22x |
|
TBPH
Theravance Biopharma, Inc.
|
16.08% | 0.410 | 6.03% | 9.30x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ASRT
Assertio Holdings, Inc.
|
$30.2M | $12.9M | -18.41% | -25.86% | 26.09% | -$4.8M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
FGEN
FibroGen, Inc.
|
$942K | -$5.4M | -- | -- | -499.07% | -$1.9M |
|
MYO
Myomo, Inc.
|
$6.4M | -$3.5M | -46.49% | -68.35% | -34.86% | -$2.9M |
|
SKYE
Skye Bioscience, Inc.
|
-$178.9K | -$13.3M | -91.01% | -91.57% | -- | -$13.4M |
|
TBPH
Theravance Biopharma, Inc.
|
$18.6M | -$6.5M | 11.74% | 14.9% | -32.29% | -$6.5M |
Assertio Holdings, Inc. vs. Competitors
-
Which has Higher Returns ASRT or CATX?
Perspective Therapeutics, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of -12425.36%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital ASRTAssertio Holdings, Inc.61.01% $0.11 $150.8M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About ASRT or CATX?
Assertio Holdings, Inc. has a consensus price target of $2.66, signalling upside risk potential of 303.41%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 349.19%. Given that Perspective Therapeutics, Inc. has higher upside potential than Assertio Holdings, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Assertio Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASRTAssertio Holdings, Inc.2 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is ASRT or CATX More Risky?
Assertio Holdings, Inc. has a beta of 0.555, which suggesting that the stock is 44.5% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock ASRT or CATX?
Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASRT or CATX?
Assertio Holdings, Inc. quarterly revenues are $49.5M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Assertio Holdings, Inc.'s net income of $11.4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 0.47x versus 190.87x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASRTAssertio Holdings, Inc.0.47x -- $49.5M $11.4M CATXPerspective Therapeutics, Inc.190.87x -- $209K -$26M
-
Which has Higher Returns ASRT or FGEN?
FibroGen, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of -1221.75%. Assertio Holdings, Inc.'s return on equity of -25.86% beat FibroGen, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ASRTAssertio Holdings, Inc.61.01% $0.11 $150.8M FGENFibroGen, Inc.87.55% $36.71 $38.5M -
What do Analysts Say About ASRT or FGEN?
Assertio Holdings, Inc. has a consensus price target of $2.66, signalling upside risk potential of 303.41%. On the other hand FibroGen, Inc. has an analysts' consensus of $43.00 which suggests that it could grow by 400.87%. Given that FibroGen, Inc. has higher upside potential than Assertio Holdings, Inc., analysts believe FibroGen, Inc. is more attractive than Assertio Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASRTAssertio Holdings, Inc.2 0 0 FGENFibroGen, Inc.0 1 0 -
Is ASRT or FGEN More Risky?
Assertio Holdings, Inc. has a beta of 0.555, which suggesting that the stock is 44.5% less volatile than S&P 500. In comparison FibroGen, Inc. has a beta of 0.747, suggesting its less volatile than the S&P 500 by 25.347%.
-
Which is a Better Dividend Stock ASRT or FGEN?
Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FibroGen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. FibroGen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASRT or FGEN?
Assertio Holdings, Inc. quarterly revenues are $49.5M, which are larger than FibroGen, Inc. quarterly revenues of $1.1M. Assertio Holdings, Inc.'s net income of $11.4M is higher than FibroGen, Inc.'s net income of -$13.1M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while FibroGen, Inc.'s PE ratio is 0.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 0.47x versus 29.24x for FibroGen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASRTAssertio Holdings, Inc.0.47x -- $49.5M $11.4M FGENFibroGen, Inc.29.24x 0.22x $1.1M -$13.1M
-
Which has Higher Returns ASRT or MYO?
Myomo, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of -36.3%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Myomo, Inc.'s return on equity of -68.35%.
Company Gross Margin Earnings Per Share Invested Capital ASRTAssertio Holdings, Inc.61.01% $0.11 $150.8M MYOMyomo, Inc.63.84% -$0.09 $26.9M -
What do Analysts Say About ASRT or MYO?
Assertio Holdings, Inc. has a consensus price target of $2.66, signalling upside risk potential of 303.41%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that Myomo, Inc. has higher upside potential than Assertio Holdings, Inc., analysts believe Myomo, Inc. is more attractive than Assertio Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASRTAssertio Holdings, Inc.2 0 0 MYOMyomo, Inc.4 0 0 -
Is ASRT or MYO More Risky?
Assertio Holdings, Inc. has a beta of 0.555, which suggesting that the stock is 44.5% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.
-
Which is a Better Dividend Stock ASRT or MYO?
Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASRT or MYO?
Assertio Holdings, Inc. quarterly revenues are $49.5M, which are larger than Myomo, Inc. quarterly revenues of $10.1M. Assertio Holdings, Inc.'s net income of $11.4M is higher than Myomo, Inc.'s net income of -$3.7M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 0.47x versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASRTAssertio Holdings, Inc.0.47x -- $49.5M $11.4M MYOMyomo, Inc.1.00x -- $10.1M -$3.7M
-
Which has Higher Returns ASRT or SKYE?
Skye Bioscience, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of --. Assertio Holdings, Inc.'s return on equity of -25.86% beat Skye Bioscience, Inc.'s return on equity of -91.57%.
Company Gross Margin Earnings Per Share Invested Capital ASRTAssertio Holdings, Inc.61.01% $0.11 $150.8M SKYESkye Bioscience, Inc.-- -$0.32 $33.2M -
What do Analysts Say About ASRT or SKYE?
Assertio Holdings, Inc. has a consensus price target of $2.66, signalling upside risk potential of 303.41%. On the other hand Skye Bioscience, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 888.73%. Given that Skye Bioscience, Inc. has higher upside potential than Assertio Holdings, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Assertio Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASRTAssertio Holdings, Inc.2 0 0 SKYESkye Bioscience, Inc.4 2 0 -
Is ASRT or SKYE More Risky?
Assertio Holdings, Inc. has a beta of 0.555, which suggesting that the stock is 44.5% less volatile than S&P 500. In comparison Skye Bioscience, Inc. has a beta of 2.676, suggesting its more volatile than the S&P 500 by 167.642%.
-
Which is a Better Dividend Stock ASRT or SKYE?
Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Skye Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Skye Bioscience, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASRT or SKYE?
Assertio Holdings, Inc. quarterly revenues are $49.5M, which are larger than Skye Bioscience, Inc. quarterly revenues of --. Assertio Holdings, Inc.'s net income of $11.4M is higher than Skye Bioscience, Inc.'s net income of -$12.8M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Skye Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 0.47x versus 476.49x for Skye Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASRTAssertio Holdings, Inc.0.47x -- $49.5M $11.4M SKYESkye Bioscience, Inc.476.49x -- -- -$12.8M
-
Which has Higher Returns ASRT or TBPH?
Theravance Biopharma, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of 18.08%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Theravance Biopharma, Inc.'s return on equity of 14.9%.
Company Gross Margin Earnings Per Share Invested Capital ASRTAssertio Holdings, Inc.61.01% $0.11 $150.8M TBPHTheravance Biopharma, Inc.92.96% $0.07 $277.3M -
What do Analysts Say About ASRT or TBPH?
Assertio Holdings, Inc. has a consensus price target of $2.66, signalling upside risk potential of 303.41%. On the other hand Theravance Biopharma, Inc. has an analysts' consensus of $26.71 which suggests that it could grow by 42.63%. Given that Assertio Holdings, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe Assertio Holdings, Inc. is more attractive than Theravance Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASRTAssertio Holdings, Inc.2 0 0 TBPHTheravance Biopharma, Inc.5 2 0 -
Is ASRT or TBPH More Risky?
Assertio Holdings, Inc. has a beta of 0.555, which suggesting that the stock is 44.5% less volatile than S&P 500. In comparison Theravance Biopharma, Inc. has a beta of 0.143, suggesting its less volatile than the S&P 500 by 85.696%.
-
Which is a Better Dividend Stock ASRT or TBPH?
Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theravance Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Theravance Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASRT or TBPH?
Assertio Holdings, Inc. quarterly revenues are $49.5M, which are larger than Theravance Biopharma, Inc. quarterly revenues of $20M. Assertio Holdings, Inc.'s net income of $11.4M is higher than Theravance Biopharma, Inc.'s net income of $3.6M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Theravance Biopharma, Inc.'s PE ratio is 33.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 0.47x versus 11.75x for Theravance Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASRTAssertio Holdings, Inc.0.47x -- $49.5M $11.4M TBPHTheravance Biopharma, Inc.11.75x 33.30x $20M $3.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
